Towers, Greg J.

HIV-1 Capsid-Cyclophilin Interactions Determine Nuclear Import Pathway, Integration Targeting and Replication Efficiency

Schaller, T., Ocwieja, K. E., Rasaiyaah, J., Price, A. J., Brady, T. L., Roth, S. L., Hué, S., Fletcher, A. J., Lee, K., KewalRamani, V. N., et al. (2011) · PLoS Pathogens

HIV Research and TreatmentVirus-based gene therapy research

Cited by 470

HIV Integration Targeting: A Pathway Involving Transportin-3 and the Nuclear Pore Protein RanBP2

Ocwieja, K. E., Brady, T. L., Ronen, K., Huegel, A., Roth, S. L., Schaller, T., James, L. C., Towers, G. J., Young, J. A. T., Chanda, S. K., et al. (2011) · PLoS Pathogens

HIV Research and TreatmentVirus-based gene therapy research

Cited by 212

Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis

Warne, J., Pryce, G., Hill, J. M., Shi, X., Lennerås, F., Puentes, F., Kip, M., Hilditch, L., Walker, P., Simone, M. I., et al. (2016) · Journal of Biological Chemistry

Mitochondrial Function and PathologySignaling Pathways in Disease

Cited by 99

Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant

Thorne, L. G., Bouhaddou, M., Reuschl, A.-K., Zuliani-Alvarez, L., Polacco, B., Pelin, A., Batra, J., Whelan, M. V. X., Ummadi, M., Rojc, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory)

SARS-CoV-2 and COVID-19 Researchinterferon and immune responses

Cited by 91

Full-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays

Gupta, R. K., Kohli, A., McCormick, A. L., Towers, G. J., Pillay, D., & Parry, C. M. (2010) · AIDS

HIV/AIDS drug development and treatmentHIV Research and Treatment

Cited by 71